DOCSLIB.ORG

Glossary of Words COVID-19 DICTIONARY for DUMMIES Terminology to Understand the Pandemic by Luis B

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glossary of Words COVID-19 DICTIONARY for DUMMIES Terminology to Understand the Pandemic by Luis B © 2021 PostScripts Publications Glossary of Words COVID-19 DICTIONARY FOR DUMMIES Terminology to Understand the Pandemic by Luis B. Vega Glossary of Words COVID-19 DICTIONARY For Dummies Terminology to Understand the Pandemic INCLUDING BIBLICAL TERMS AND CONCEPTS HACKING INTO THE GENOME OF ADAM _______________________________________ LUIS BERNARDINO VEGA 2 Dedicated to Those Choosing to receive the COVID-19 Shots. 3 Table of Contents Prologue………………………………….................... 5 Glossary of Words……………………….………..….. 8 Home Treatments……………..……...………………. 53 Scientific Diagrams…………………...………………. 58 ABC’s of Salvation……………………………………. 82 References…………………………………………….. 88 4 Prologue ‘By controlling the language, Big Brother controls the way that the People think. With a Limited Vocabulary, the People are limited in how much they can think, as well as, what they think about.’ - Orwell's 1984 The purpose of this booklet is to provide the Reader with a comprehensive array of the major Scientific, Medical, Political and some Theological terms concerning the COVID-19 pandemic. Why? The objective is to have a better sense of what the words, terms, and concepts mean. It is to be better educated in understanding such words when coming across either Scientists, Doctors, Virologists, Politicians and even Theologians who use them. Why? To make a more informed decision as to whether to take the new mRNA shots for example. Realize that the current narrative of what is going on with the COVID-19 pandemic and the new mRNA shots being administered needs to have a balanced approach in terms of a healthy, open and democratic debate. This is not occurring. On one hand, there is the ‘Official State Narrative’ and of the Facts and Figures posted on such websites of the UN’s World Health Organization WHO and the U.S. Centers for Disease Control and Prevention CDC, among others that cannot be either questioned or criticized. Then on the other hand, there are those dissenting voices of concern that are coming mainly from the same Scientific Community that are challenging the Official Narrative, Facts and Figures. However, this group of Scientists, Virologists, and Doctors are being censored, de-platformed or are afraid to speak out. Why? To this end, the aim of this booklet is to provide the vocabulary so as to follow along, if and when one comes across this 2nd group in an interview, a publication, a debate or presentation. One realizes that the degree of understanding and comprehending the terms might be limited when it comes to the topic of COVID. For example, many may not realize the complexity of what the COVID-19 shots do or will do or could do. Most are not questioning the narrative. They say, ‘Trust the Science’. Or ‘Do what the Doctors say’? Is this ‘Blind Faith’? Can one explain how one gest Infected, or Transmits a disease? The terms which are very Scientific and Medical, can put-off most Readers or the average person. In some cases, the terminology gives one a flashback to a High School or College Biology course. Nonetheless, the challenge is to provide a summary of the most common words, terms, ideas and/or thoughts pertaining to the COVID-19 pandemic. One’s life may depend on it, especially if one is asking questions or seeking an understanding that goes beyond the Morning and/or Evening News Programing. The following terms, 5 in this ‘COVID Dictionary’ are defined from the online sites, mainly Merriam- Webster, Wikipedia, and other sources. The terms are specifically the ones that are used when such Scientists, Doctors Politicians and/or Theologians speak on the matter of the Pandemic and/or the shots. Why is it important? Consider that such Medical, Scientific or Theological terms that reference research or assessments pertaining to COVID are directly affecting you and set then the various Health Policies. The last reason why such a COVID-19 Dictionary is pertinent to the pandemic is that it will help when one is personally engaged in arguments, debates or writings with others. It can be either with Family Members, work Colleagues or People in public. After reviewing the terms, one would hope that one will be more prepared to present their points of view with a deeper appreciation, understanding and comprehension of what the COVID-19 pandemic is all about and what the mRNA shots are. Are they even a vaccine? Is it really Gene Therapy as some would purport? Will it change one’s DNA then? The terms will educated you and answer those questions very clearly. Thus, one will be hopefully able to follow the discussions and terms when engages in a conversion, with few and the many, etc. One will hopefully be able to follow along with the Scientific and Medical terminology used by the various Doctors, Scientist, Politicians and Theologians, on both sides of the debate recognizing the arguments for and against the ‘Science’ and ‘Biology’ that is being imposed on Humanity presently. Indeed, the words, terms and concepts of this COVID-19 Dictionary will comprise an array of terms one would find in an introductory University Biology textbook. Buy one will include a Biblical overlay of terms as well. Why involve Theology in with this Science and Medicine? It is because the Science and Medicine will both soon become Theology per the Bible, and specifically pertinent to its last book, Revelation. While there is that1st and 2nd group of competing Scientific and Medical interpretation about the nature of the pandemic, the Lockdowns, Quarantining, Mask Wearing and restricted travel, there is a 3rd Group. As mentioned, that is of the Theologians that likewise raise the alarm of the social and moral implications of the pandemic, its Public Health Policy, and the mRNA shots. One believes that this facet is just as important as millions have suffered greatly, psychologically because of the isolations and detachments from family and friends and society in general. Many have sought, are seeking for Divine Guidance, help, solace and answers, especially of one’s that have had Loved Ones die because of this pandemic. The point is that this Theological perspective should be considered as well. To that end, some of the terminology will be Theological to describe and ascribe what is going on presently, especially with the mRNA shots, that to some, are converging with Biblical prophecy, it would appear. But to be clear, this booklet is geared to 6 those that do have or will have a Judeo-Christian disposition of incorporating such Theological terms in the Glossary. Or are open to the perspective of the pandemic from this point of view in considering some of the Scientific, Medical and Theological terms. The format the Glossary will have, at time portions of the text in highlight, underlined, or in bold. Numbers from 1 to 10 will be numerated and in some cases, capitalization will be ascribed for emphasis purposes only. 7 Glossary of Words 4th Industrial Revolution The ongoing automation of Traditional Manufacturing and Industrial Practices, using modern Smart Technology where Man merges with Machine. 5G The 5th Generation technology standard for Broadband Cellular Networks, which cellular phone companies began deploying worldwide in 2019. There is 6G, 7G to come. _____________________________ A Aborted Fetal Tissue The use of Cell Line that were originally derived from the tissue of an Aborted Baby. Abortion The ending of a Live Pregnancy by removal or expulsion of a Human Being at the Embryo or Fetus developmental stage. Most Religious Institutions consider this ‘Medical Procedure’, murder. Acquired Immune Deficiency Syndrome or AIDS It is a chronic, potentially life-threatening condition caused by the Human Immunodeficiency Virus (HIV). By damaging the Immune System, HIV interferes with your body's ability to fight infection and disease. HIV is a Sexually Transmitted Infection (STI). Adam A genetic Human Being in the book of Genesis of the Bible that was the first Man created by YHVH, the Creator. Adam and his Wife were expelled from the Garden of Eden for eating fruit from the Tree of Knowledge of Good and Evil. Adam 2.0 The concept that the synchronization of the 4th Industrial Revolution combined with Artificial Intelligence A.I., and the new mRNA COVID-19 Gene Therapy shot will construe a new Humanity to the next evolutionary level that merges Man with Machine through the ability to re-Program the Human Genome. (Luis B. Vega) 8 Adaptive Advantage It is a powerful concept for facing Unstable Environments. It involves not only different ways of operating but also very different ways of thinking about strategy. Adverse Event It is any Untoward Medical Occurrence in a Patient or Clinical Investigation Subject, administered a Pharmaceutical Product and which does not necessarily have a causal relationship with this Treatment. Agent Orange It is an Herbicide and Defoliant Chemical, one of the Tactical Use Rainbow Herbicides. It is widely known for its use by the U.S. Military as part of its Herbicidal Warfare Program, Operation Ranch Hand, during the Vietnam War from 1961 to 1971. The government of Vietnam says that 4 million of its citizens were exposed to Agent Orange, and as many as 3 million have suffered illnesses because of it. Airborne Viruses They are capable of becoming suspended in the air, typically when an Infected individual coughs or sneezes. They can then be inhaled by unsuspecting individuals resulting in new infections. Airborne viruses can affect both animals and humans. Algorithm In Mathematics and Computer Science, an Algorithm is a Finite Sequence of well- defined, computer-implementable instructions, typically to solve a class of problems or to perform a computation. Algorithms are always unambiguous and are used as specifications for performing calculations, data processing, automated reasoning, etc. Allergies They are an Immune System Response to a foreign substance that are not typically harmful to the body.
Load more

Recommended publications
  • National Lipid Association Annual Summary of Clinical Lipidology 2015
    Journal of Clinical Lipidology (2014) 8, S1-S36 Original Contribution National Lipid Association Annual Summary of Clinical Lipidology 2015 Harold E. Bays, MD, FTOS, FACC, FACE, FNLA*, Peter H. Jones, MD, FACP, FNLA, W. Virgil Brown, MD, FNLA, Terry A. Jacobson, MD, FACP, FNLA Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr Bays); Baylor College of Medicine, Houston, TX, USA (Dr Jones); Emory University School of Medicine, Atlanta, GA, USA (Dr Brown); and Department of Medicine, Emory University, Atlanta, GA, USA (Dr Jacobson) KEYWORDS: Abstract: The National Lipid Association (NLA) Annual Summary of Clinical Lipidology 2015 is a Clinical Lipidology; summary of principles important to the patient-centered evaluation, management, and care of patients Dyslipidemia; with dyslipidemia. This summary is intended to be a ‘‘living document,’’ with future annual updates National Lipid based on emerging science, clinical considerations, and new NLA Position and Consensus Statements. Association; The goal is to provide clinicians an ongoing resource that translates the latest advances in medical Annual Summary; science toward the evaluation and treatment of patients with dyslipidemia. The 2015 NLA Annual Cholesterol; Summary of Clinical Lipidology was founded on the principles of evidence-based medicine and is Recommendations; generally consistent with established national and international lipid guidelines. Topics include a Guidelines general discussion of the 2014 NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, secondary causes of dyslipidemia, biomarkers and ‘‘advanced lipid testing,’’ medical nutrition, physical activity, obesity, pharmacotherapy, statin safety, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia in children and adolescence, dyslipidemia in older individuals, race/ethnicity, and women, health information technology and electronic medical records, as well as investigational lipid-altering drugs in development.
    [Show full text]
  • Geeta Sikand, MS
    Geeta Sikand, MA, RDN, FAND, CDE, CLS, FNLA Geeta Sikand is an Associate Clinical Professor of Medicine in Cardiology at the University of California, Irvine School of Medicine. Registered Dietitian Nutritionist, Clinical Lipid Specialist, Certified Diabetes Educator, Fellow of the National Lipid Association and Fellow of the Academy of Nutrition and Dietetics. Ms Sikand is Director of Nutrition at University of California Irvine Preventive Cardiology Program. Ms Sikand is the recipient of the 2016 Lifetime Achievement Award from the Academy of Nutrition and Dietetics Member Interest Group, the 2013 Distinguished Service Award from the Dietitians’ in Health Care Communities Practice Group. For her research on the effectiveness of medical nutrition therapy in dyslipidemia, Geeta was the 2001 recipient of the Academy of Nutrition & Dietetics prestigious "Mary Huddleson Award” and the 1997 Excellence in Research Award from the California Academy of Nutrition and Dietetics. Ms Sikand is Chair, Medical Nutrition Therapy Effectiveness Expert Workgroup of the Academy of Nutrition & Dietetics and served as Expert Member of the Disorders of Lipid Metabolism Expert Panel. Ms Sikand has served on the Board of Directors of the American Heart Association and as Vice President of Public Policy for California Dietetic Association. As President of California Dietetic Association: Orange District and Chair of Southern California Legislative Steering Committee Ms Sikand organized the first ever onsite Congressional visit with Congressman Ron Packard to seek his support for the Medicare medical nutrition therapy legislation which passed in 1996. Ms Sikand is a member of the Pacific Lipid Association (PLA) and has served on the National Lipid Association (NLA) Expert Panel “Recommendations for Patient Centered Management of Dyslipidemia” published in December 2015.
    [Show full text]
  • National Lipid Association Annual Summary of Clinical Lipidology 2016
    Journal of Clinical Lipidology (2016) 10, S1-S43 National Lipid Association Annual Summary of Clinical Lipidology 2016 Harold E. Bays, MD, FNLA*, Peter H. Jones, MD, FNLA, Carl E. Orringer, MD, FNLA, W. Virgil Brown, MD, FNLA, Terry A. Jacobson, MD, FNLA Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr Bays); Baylor College of Medicine, Houston, TX, USA (Dr Jones); University of Miami Leonard M. Miller School of Medicine, Miami, FL (Dr Orringer); Emory University School of Medicine, Atlanta, GA, USA (Dr Brown); and Department of Medicine, Emory University, Atlanta, GA, USA (Dr Jacobson) KEYWORDS: Abstract: The National Lipid Association (NLA) Annual Summary of Clinical Lipidology is a yearly Clinical Lipidology; updated summary of principles important to the patient-centered evaluation, management, and care Dyslipidemia; of patients with dyslipidemia. This summary is intended to be a ‘‘living document,’’ with future annual National Lipid updates based on emerging science, clinical considerations, and new NLA Position, Consensus, and Association; Scientific Statements, thus providing an ongoing resource that applies the latest in medical science to- Annual Summary; wards the clinical management of patients with dyslipidemia. Topics include the NLA Recommenda- Cholesterol; tions for Patient-Centered Management of Dyslipidemia, genetics, Familial Hypercholesterolemia, Recommendations; secondary causes of dyslipidemia, biomarkers and advanced lipid testing, nutrition, physical activity, Guidelines obesity, adiposopathy, metabolic syndrome, diabetes mellitus, lipid pharmacotherapy, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia management and treatment based upon age (chil- dren, adolescents, and older individuals), dyslipidemia considerations based upon race, ethnicity and gender, dyslipidemia and human immune virus infection, dyslipidemia and immune disorders, adher- ence strategies and collaborative care, and lipid-altering drugs in development.
    [Show full text]
  • Improving Pre-Trained Multilingual Model with Vocabulary Expansion
    Improving Pre-Trained Multilingual Models with Vocabulary Expansion Hai Wang1* Dian Yu2 Kai Sun3* Jianshu Chen2 Dong Yu2 1Toyota Technological Institute at Chicago, Chicago, IL, USA 2Tencent AI Lab, Bellevue, WA, USA 3Cornell, Ithaca, NY, USA [email protected], [email protected], fyudian,jianshuchen,[email protected] i.e., out-of-vocabulary (OOV) words (Søgaard and Abstract Johannsen, 2012; Madhyastha et al., 2016). A higher OOV rate (i.e., the percentage of the unseen Recently, pre-trained language models have words in the held-out data) may lead to a more achieved remarkable success in a broad range severe performance drop (Kaljahi et al., 2015). of natural language processing tasks. How- ever, in multilingual setting, it is extremely OOV problems have been addressed in previous resource-consuming to pre-train a deep lan- works under monolingual settings, through replac- guage model over large-scale corpora for each ing OOV words with their semantically similar in- language. Instead of exhaustively pre-training vocabulary words (Madhyastha et al., 2016; Ko- monolingual language models independently, lachina et al., 2017) or using character/word infor- an alternative solution is to pre-train a pow- mation (Kim et al., 2016, 2018; Chen et al., 2018) erful multilingual deep language model over or subword information like byte pair encoding large-scale corpora in hundreds of languages. (BPE) (Sennrich et al., 2016; Stratos, 2017). However, the vocabulary size for each lan- guage in such a model is relatively small, es- Recently, fine-tuning a pre-trained deep lan- pecially for low-resource languages. This lim- guage model, such as Generative Pre-Training itation inevitably hinders the performance of (GPT) (Radford et al., 2018) and Bidirec- these multilingual models on tasks such as se- tional Encoder Representations from Transform- quence labeling, wherein in-depth token-level ers (BERT) (Devlin et al., 2018), has achieved re- or sentence-level understanding is essential.
    [Show full text]
  • Ministry of Education and Youth of the Republic Of
    MINISTRY OF EDUCATION OF THE REPUBLIC OF MOLDOVA MOLDOVA STATE UNIVERSITY FACULTY OF FOREIGN LANGUAGES AND LITERATURES DEPARTMENT OF TRANSLATION, INTERPRETATION AND APPLIED LINGUISTICS MASTER’S DEGREE PAPER A CONTRASTIVE ANALYSIS OF LEGAL TERMINOLOGY IN ENGLISH, ROMANIAN AND POLISH. LEGAL TERMINOLOGY INNOVATIONS IN THE REPUBLIC OF MOLDOVA Submitted by: Buşila Alina, group 262 Research Adviser: Şaganean Gabriela, Doctor of Philology Chişinău 2011 TABLE OF CONTENTS Annotation ……………………………………………………………………………...…3 Adnotare ………………………………………………………………………………..…4 List of abbreviations …………………………………………………………………..….5 INTRODUCTION ……………………………………………………………………………..….6 CHAPTER I. LINGUISTIC APPROACH ON LEGAL TERMINOLOGY …………….…..12 1.1 Introduction in Terminology. Definitions and Controversy upon Terminology 1.2 Term versus Word versus Concept …………………………………………….19 1.3 Semantics of Legal Terminology ………………………………………………20 1.4 Recent Trends in Terminology ………………………………………………...24 1.5 Multilingual Term Creation within the EU Conceptual System ………………26 1.6 Characteristics of Terms ……………………………………………………….28 1.6.1 Different Classifications of Terms …………………………………...33 1.6.2 The Process of Terminologization, Determinologization and Reterminologization ……………………………………………………….46 1.7 Legal Terminology …………………………………………………………….48 1.7.1 English, Romanian and Polish Legal Terminology ………………….51 1.7.2 Incongruity of Legal Terms ………………………………………….53 1.7.3 Translation of Legal Terms ………………………………………….55 1.7.4 Legal Terminology Innovations in the Republic of Moldova ……….59 CHAPTER
    [Show full text]
  • Preventive Cardiology / Advanced Lipidology Clinical Fellowship
    Preventive Cardiology / Advanced Lipidology Clinical Fellowship Name of Institution: McGill University Health Centre Location: Cardiology Division, MUHC RVH Site, 687 Pine Avenue West Montreal, QC, H3A 1A1 MUHC RI, Cardiology Research Laboratories Type of Fellowship: Preventive Cardiology / Advanced Lipidology fellowship training program Duration: 1 year (Clinical and clinical research) Program Information This fellowship is offered to residents having completed Internal Medicine Residency, Medical Biochemistry Residency or Cardiology Residency. Exceptionally, physicians having completed family practice will be considered. Number of fellowship positions requested: One fellow per supervisor. Every fellowship will be reviewed to ensure that there are the appropriate resources for the fellow in terms of an educational experience. Training sites: McGill University Health Center Hospital involved in training: Royal Victoria Hospital where candidate will spend most of the time. Requirement: licensed MD who has completed a formal training program as outlined above. Scholarly activity will mainly be in research in the field of lipidology, and fellows will be expected to design and execute at least one research project in the area of atherosclerosis pathogenesis or lipid management during their training period. They will also be expected to work on publications. Areas of research experience to be emphasized include research design, recruitment techniques, data acquisition, and analysis. The fellow will be encouraged to present the research at national meetings and publish the data in established, peer-reviewed journals. The mission is to promote and advocate the understanding of dyslipidemia and primary prevention. The primary goal of this specialized training is to reduce the morbidity and mortality from dyslipidemia and related diseases by bridging basic knowledge and recent understanding of the vascular biology and their relevance to the basis of high risk screening and prevention of disease in a clinical setting.
    [Show full text]
  • JOURNAL of CLINICAL LIPIDOLOGY Official Journal of the National Lipid Association
    JOURNAL OF CLINICAL LIPIDOLOGY Official Journal of the National Lipid Association AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.1 • Impact Factor p.2 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.5 ISSN: 1933-2874 DESCRIPTION . The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
    [Show full text]
  • SIRT1 Regulates Sphingolipid Metabolism and Neural
    RESEARCH ARTICLE SIRT1 regulates sphingolipid metabolism and neural differentiation of mouse embryonic stem cells through c-Myc- SMPDL3B Wei Fan1, Shuang Tang1†, Xiaojuan Fan2, Yi Fang1, Xiaojiang Xu3, Leping Li4, Jian Xu5, Jian-Liang Li3, Zefeng Wang2*, Xiaoling Li1* 1Signal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Triangle Park, United States; 2CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China; 3Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Research Triangle Park, Triangle Park, United States; 4Biostatistics & Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, Triangle Park, United States; 5Children’s Medical Center Research Institute, Department of Pediatrics, Harold C. Simmons Comprehensive Cancer *For correspondence: Center, and Hamon Center for Regenerative Science and Medicine, University of [email protected] (ZW); Texas Southwestern Medical Center, Dallas, United States [email protected] (XL) Present address: †Cancer Institute and Department of Nuclear Medicine, Fudan Abstract Sphingolipids are important structural components of cell membranes and prominent University Shanghai Cancer signaling
    [Show full text]
  • Genetics and Mainstream Medicine
    Genetics and mainstream medicine Service development and integration March 2011 Author: Hilary Burton Acknowledgements The author would like to acknowledge with thanks the expert guidance and support of Dr Ron Zimmern and Dr Peter Farndon. The initial work was funded by the UK Genetic Testing Network. However, this final report is published independently by the PHG Foundation. This report can be downloaded from our website: www.phgfoundation.org Published by PHG Foundation 2 Worts Causeway Cambridge CB1 8RN UK Tel: +44 (0) 1223 740200 Fax: +44 (0) 1223 740892 © 2011 PHG Foundation ISBN 978-1-907198-07-6 Correspondence to the author: [email protected] How to reference this report: Genetics and mainstream medicine. PHG Foundation (2011) ISBN 978-1-907198-07-6 The PHG Foundation is the working name of the Foundation for Genomics and Population Health, an independent charitable organisation (registered in England and Wales, charity No. 1118664 company No. 5823194), which works with partners to achieve better health through the responsible and evidence-based application of biomedical science. Genetics and mainstream medicine – service development and integration Table of Contents Key policy points ...............................................................................3 1 Introduction ..............................................................................7 2 Background ...............................................................................9 3 Methods ................................................................................
    [Show full text]
  • Queering Polyamory: Configurations, Public Policy, and Lived Experiences
    Queering Polyamory: Configurations, Public Policy, and Lived Experiences By Timothy Joseph Gardner A Thesis Submitted in Partial Fulfillment of the Requirements for Master of Science in Ethnic and Multi-cultural Studies College of Behavioral and Social Sciences Minnesota State University, Mankato Mankato, Minnesota May 2005 ii iii This work is licensed under the Creative Commons Attribution-NonCommercial- NoDerivs License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/2.0/ or send a letter to Creative Commons, 559 Nathan Abbott Way, Stanford, California 94305, USA. iv ABSTRACT Gardner J. Timothy 2005 Queering Polyamory: Configurations, Public Policy, and Lived Experiences. M.S. thesis, Ethnic and Multi-cultural Studies, Minnesota State University, Mankato, 100 leaves. “Queering Polyamory: Configurations, Public Policy, and Lived Experiences” explores polyamory, a relationship “lovestyle” that involves more then one loving partner, while taking a close look at the social construction of modern day queer polyamory including marriage and sex law. The author states that queer polyamory is socially constructed due to its inclusion of self-identifying gay men, lesbian, bisexual, transgender, transsexual, gender-variant, omnisexual, pansexual, and queer individuals. This thesis includes a study of participants involved in queer polyamorous relationships. The study concludes that a population that engages in queer polyamorous relationships is diverse in regards to demographics; this is to say state of residence, age, gender, ethnicity, religious/spiritual affiliation, sexual identity and/or orientation, and relationship identity and/or orientation and ways individuals come to be part of queer polyamorous relationships. The study looks at how “out” the participants are and how public policy is affecting the lives of those who engage in queer polyamorous relationships.
    [Show full text]
  • 2015 National Lipid Association
    Journal of Clinical Lipidology (2015) -, -–- Original Contribution National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD*, Matthew K. Ito, PharmD, Kevin C. Maki, PhD, Carl E. Orringer, MD, Harold E. Bays, MD, Peter H. Jones, MD, James M. McKenney, PharmD, Scott M. Grundy, MD, PhD, Edward A. Gill, MD, Robert A. Wild, MD, PhD, Don P. Wilson, MD, W. Virgil Brown, MD Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA (Dr Jacobson); Oregon State University/Oregon Health & Science University, College of Pharmacy, Portland, OR, USA (Dr Ito); Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL, USA (Dr Maki); University of Miami Health System, Miami, FL, USA (Dr Orringer); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr Bays); Baylor College of Medicine, Houston, TX, USA (Dr Jones); Virginia Commonwealth University and National Clinical Research, Richmond, VA, USA (Dr McKenney); The University of Texas Southwestern Medical Center, Dallas, TX, USA (Dr Grundy); University of Washington/Harborview Medical Center, Seattle, WA, USA (Dr Gill); Oklahoma University Health Sciences Center, Oklahoma City, OK, USA (Dr Wild); Cook Children’s Medical Center, Fort Worth, TX, USA (Dr Wilson); and Emory University School of Medicine, Atlanta, GA, USA (Dr Brown) KEYWORDS: Abstract: The leadership of the National Lipid Association convened an Expert Panel to develop a Clinical consensus set of recommendations for patient-centered management of dyslipidemia in clinical med- recommendations; icine. An Executive Summary of those recommendations was previously published. This document Dyslipidemia; provides support for the recommendations outlined in the Executive Summary.
    [Show full text]
  • Therapeutic Lipidology
    springer.com Medicine : Cardiology Davidson, M.H., Toth, P.P., Maki, K.C. (Eds.) Therapeutic Lipidology Provides comprehensive coverage of all core aspects of clinical lipidology as well as relevant basic science and dyslipidemia management strategies Updated to include new guidelines, novel therapeutic agents, and changes in the understanding of specific lipids/lipoproteins and cardiovascular disease risk Highlights recent advances in the field such as novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, as well as imaging technologies and lipoprotein separation/measurement methodologies The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease. The book describes Humana new guidelines, novel therapeutic agents, and changes in the understanding of specific 2nd ed. 2021, XV, 689 p. lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. 2nd 140 illus., 114 illus. in color. edition The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle /dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an Printed book examination of other biomarkers and testing procedures related to atherosclerosis and Hardcover cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource Printed book for physicians, medical students, residents, fellows, and allied health professionals in lipidology, Hardcover cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.
    [Show full text]